Literature DB >> 3971658

A Bayesian feedback method of aminoglycoside dosing.

M E Burton, D C Brater, P S Chen, R B Day, P J Huber, M R Vasko.   

Abstract

We assessed the accuracy of a Bayesian method in providing dosing regimens to achieve desired serum aminoglycoside concentrations. This method calculates individual kinetics based on serum drug concentration data. Performance was analyzed by determining accuracy, bias, correlations of observed to desired serum drug concentrations, and the ability to achieve a target serum drug concentration. We also compared results from the Bayesian method with those resulting from the use of the predictive algorithm portion of the computer program and with routine physician dosing. The Bayesian method resulted in a high correlation coefficient (r = 0.913) between observed and predicted serum concentrations. Analysis of peak aminoglycoside concentrations indicated that the Bayesian method was more accurate and less biased than the predictive algorithm portion of the program or routine physician dosing. A similar trend occurred for trough concentrations. Finally, there were no statistically significant differences between the predicted and observed peak (6.4 +/- 1.5 and 5.9 +/- micrograms/ml) and trough (1.2 +/- 0.9 and 1.4 +/- 0.8 micrograms/ml) serum aminoglycoside concentrations with the Bayesian dosing method. There were significant differences for peak concentrations with the predictive algorithm portion of the program and for peak and trough concentrations with physician dosing. These data demonstrate the accuracy of the Bayesian dosing method in attaining desired peak and trough serum aminoglycoside concentrations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3971658     DOI: 10.1038/clpt.1985.51

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy.

Authors:  Lana Nezic; Adrian Derungs; Marcel Bruggisser; Sarah Tschudin-Sutter; Stephan Krähenbühl; Manuel Haschke
Journal:  Eur J Clin Pharmacol       Date:  2014-04-23       Impact factor: 2.953

Review 4.  Cost-effectiveness of therapeutic drug monitoring.

Authors:  S Vozeh
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

5.  A Critique of Pharmacokinetic Calculators for Drug Dosing Individualization.

Authors:  Slobodan M Janković
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-04       Impact factor: 2.441

6.  Population pharmacokinetics of tobramycin.

Authors:  L Aarons; S Vozeh; M Wenk; P Weiss; F Follath
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 7.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

8.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

9.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 10.  An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.